Last reviewed · How we verify
S-Ketamine 0.25
S-Ketamine is an NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset anesthetic and analgesic effects.
S-Ketamine is an NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset anesthetic and analgesic effects. Used for Induction and maintenance of general anesthesia, Acute pain management, Treatment-resistant depression (investigational).
At a glance
| Generic name | S-Ketamine 0.25 |
|---|---|
| Also known as | Ketanest-S |
| Sponsor | Turku University Hospital |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Pain Management, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
S-Ketamine is the active S-enantiomer of ketamine, which acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor. This blockade interrupts excitatory neurotransmission in the central nervous system, producing dissociative anesthesia, analgesia, and sedation. The S-enantiomer is approximately 3–4 times more potent than the racemic mixture and has a faster onset and shorter duration of action.
Approved indications
- Induction and maintenance of general anesthesia
- Acute pain management
- Treatment-resistant depression (investigational)
Common side effects
- Dissociation
- Dizziness
- Nausea
- Increased blood pressure
- Tachycardia
- Hallucinations
Key clinical trials
- Efficacy and Safety of S-ketamine in Elderly Patients Undergoing Non-cardiac Surgery: a RCT（ESSENCE） (PHASE4)
- Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest (PHASE2)
- S Ketamine Use in Total Abdominal Hysterectomy (NA)
- Safety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients (PHASE4)
- Prophylactic Effects of Esketamine in Surgical Patients (PHASE4)
- Comparison of the Sedation Effect of Esketamine and Sevoflurane for Pediatric Ophthalmological Procedure (NA)
- Safety and Efficacy Evaluation of S (+) - Ketamine in Children (PHASE4)
- The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-Ketamine 0.25 CI brief — competitive landscape report
- S-Ketamine 0.25 updates RSS · CI watch RSS
- Turku University Hospital portfolio CI